Clozapine Long-Term Treatment Might Reduce Epigenetic Age Through Hypomethylation of Longevity Regulatory Pathways Genes

Blanca Estela Pérez-Aldana1, José Jaime Martínez-Magaña2, Yerye Gibrán Mayén-Lobo3, David José Dávila-Ortiz de Montellano4, Carlos Luis Aviña-Cervantes4, Alberto Ortega-Vázquez5, Alma Delia Genis-Mendoza2, Emmanuel Sarmiento6, Ernesto Soto-Reyes7, Isela Esther Juárez-Rojop8, Carlos Alfonso Tovilla-Zarate9, Thelma Beatriz González-Castro10, Humberto Nicolini2,11*, Marisol López-López3 and Nancy Monroy-Jaramillo4*

1 Doctorado en Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana, Mexico City, Mexico, 2 Laboratorio de Genómica de Enfermedades Psiquiátricas y Neurodegenerativas, Instituto Nacional de Medicina Genómica, Mexico City, Mexico, 3 Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana, Mexico City, Mexico, 4 Departamento de Genética, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico, 5 Departamento de Psiquiatría, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico, 6 Dirección General, Hospital Psiquiátrico Infantil Juan N Navarro, Mexico City, Mexico, 7 Departamento de Ciencias Naturales, Universidad Autónoma Metropolitana, Unidad Cuajimalpa, Mexico City, Mexico, 8 División Académica de Ciencias de la Salud, Universidad Juárez Autónoma de Tabasco, Villahermosa, Mexico, 9 División Académica Multidisciplinaria de Comalcalco, Universidad Juárez Autónoma de Tabasco, Comalcalco, Mexico, 10 División Académica Multidisciplinaria de Jalpa de Méndez, Universidad Juárez Autónoma de Tabasco, Jalpa de Méndez, Mexico, 11 Grupo de Estudios Médicos y Familiares Carracci, Mexico City, Mexico

Long-term studies have shown significantly lower mortality rates in patients with continuous clozapine (CLZ) treatment than other antipsychotics. We aimed to evaluate epigenetic age and DNA methylome differences between CLZ-treated patients and those without psychopharmacological treatment. The DNA methylome was analyzed using the Infinium MethylationEPIC BeadChip in 31 CLZ-treated patients with psychotic disorders and 56 patients with psychiatric disorders naïve to psychopharmacological treatment. Delta age ($\Delta$age) was calculated as the difference between predicted epigenetic age and chronological age. CLZ-treated patients were stratified by sex, age, and years of treatment. Differential methylation sites between both groups were determined using linear regression models. The $\Delta$age in CLZ-treated patients was on average lower compared with drug-naïve patients for the three clocks analyzed; however, after data-stratification, this difference remained only in male patients. Additional differences were observed in Hannum and Horvath clocks when comparing chronological age and years of CLZ treatment. We identified 44,716 differentially methylated sites, of which 87.7% were hypomethylated in CLZ-treated patients, and...
INTRODUCTION

There is evidence of premature mortality and an increase in physical comorbidity in patients with psychiatric disorders (1). On average, their life expectancy is reduced from 12 to 15 years compared with the general population (2, 3). Some authors have proposed that the increased mortality could correlate with increased biological aging (4–6). Various epigenetic age estimators of biological age have been developed based on DNA methylation status across a set of CpG sites in cells/tissues, and these have been shown to correlate with the risk of developing age-related conditions and diseases (7–9). Moreover, the presence of psychotic symptoms is observed in different psychiatric illnesses (mainly schizophrenia and bipolar disorder), contributing to this mortality. A recent study reported a positive correlation between epigenetic aging and psychosis severity (10). Fortunately, psychotic symptoms can be controlled with the use of antipsychotics, which also help in reducing the risk of psychotic relapse (11).

On the other hand, the adverse cardiac and metabolic effects of antipsychotics are well known. However, their use in patients with schizophrenia is associated with lower mortality (12). There is evidence demonstrating a 30–50% lower risk of mortality related to the use of antipsychotics compared with non-use (13, 14). In particular, the long-term use of clozapine (CLZ) has been associated with the lowest mortality (12, 15, 16). CLZ is the antipsychotic of choice for patients with refractory psychosis (17), for reducing suicide, and for improving longevity (18). Epidemiological data (19, 20) have supported this last point. Some studies suggest that CLZ promotes epigenetic changes with pro-longevity effects (21, 22), and a recent work has proposed that CLZ may reduce epigenetic aging (23).

The present work aimed to evaluate epigenetic age and DNA methylome differences between patients treated with CLZ and psychiatric patients without psychopharmacological treatment.

MATERIALS AND METHODS

Sample Population

In this study, 87 individuals of Mexican ascendancy were included. Of them, 31 were diagnosed with refractory psychosis and treated with CLZ (CLZ-treated patients), and 56 had early onset psychiatric disorders. This last group of patients has not had any previous psychopharmacological treatment and will be called as drug-naive patients. Samples from both groups of patients were recruited from the outpatient clinics. The CLZ-treated patients with refractory psychosis were recruited from the Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez (INNNMVS), and drug-naive patients from the Hospital Psiquiátrico Infantil Juan N. Navarro and the Hospital General Dr. Gustavo Rivorosa Pérez. At least one specialized psychiatrist performed the diagnosis. Individuals with intellectual disabilities, heavy drinkers, smokers, or substance abusers were excluded. In addition, we excluded drug-naive patients who had begun psychopharmacological treatment. The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Research and Bioethics Committees of INNNMVS (protocol 38/19), the Ethics Committee of the Children’s Psychiatric Hospital Dr. Juan N. Navarro with approval No. II3/01/0913 (11 October 2017), and by the Ethics Committee of the National Institute of Genomic Medicine (INMEGEN) with approval No. 06/2018/I. Furthermore, all individuals signed informed consents. For those patients under the age of 18 years, an informed assent letter was signed by both parents/guardians and the minor.

Analysis and Quality Control of Microarrays

Blood DNA extraction, bisulfite-conversion (Zymo, Irvine, CA, United States), and microarray hybridization (Infinum MethylationEPIC BeadChip, Illumina, San Diego, CA, United States) were performed according to the manufacturer’s protocol. We used the Genome Reference Consortium Human Build 37 (GRCh37/hg19) as position reference for all the analyses. The fluorescence intensities were measured with the iScan instrument and transformed into idat files with the algorithm implemented in the GenomeStudio software (Illumina, San Diego, CA, United States). Specialized staff carried out microarray analyses in the INMEGEN. The ChAMP (24) package was used for quality control. Briefly, the probes using the following filters were removed: (i) detection \( p \) greater than 0.01, (ii) less than three beads in less than 5% of the samples, (iii) all non-CpG sites, (iv) single nucleotide polymorphism (SNP)-associated probes, (v) probes associated with sex chromosomes, and (vi) multi-hit probes. In addition, samples with a ratio greater than 0.1 were removed, resulting in one individual filtered out. After quality control, a matrix of beta values was constructed.

Epigenetic Age Calculation

We normalized the previous beta value matrix by beta-mixture quantile normalization (25) and calculated epigenetic ages with the Enmix package (26). This package allowed us to calculate three epigenetic clocks: Hannum (7), Horvath (8), and DNAm PhenoAge (9). The epigenetic ages calculated with the Horvath,
Hannum, and PhenoAge clocks and the chronological age in both groups were compared by correlation analysis. Then, we calculated the delta of age (ΔAge = epigenetic age − chronological age), subtracting the chronological age from the estimated epigenetic age in all samples and by each clock. Finally, we compared the ΔAge of each clock between CLZ-treated patients and drug-naive patients. First, stratified analysis by sex and age was carried out, comparing the CLZ-treated patients vs. drug-naive patients. The CLZ-treated patients’ group was later subdivided into subgroups according to the time’s mean of treatment with CLZ (>9 and ≤9 years of treatment; i.e., few and many years of treatment, respectively) and according to the mean chronological age (cut-off value = 37 years; i.e., young and older patients). Due to the small sample size, and to achieve mean chronological age (cut-off value = 37 years; i.e., young and many years of treatment, respectively) and according to the p-value of the t-test was applied for the analysis of significant enrichment, we achieved a sub-enrichment analysis of the differential methylation region analysis in String using the WebGestalt platform (WEB-based GEne SeT AnaLysis Toolkit) with free access (30) (all pathways of this enrichment are available on Supplementary Table 3). First, we analyzed differentially methylated sites analysis by linear models implemented in champ.DMP function of the ChAMP package (28). Then, after identifying differentially methylated sites, a differentially methylated region analysis was carried out with the ProbeLasso algorithm (29) (a summary of statistics is available in Supplementary Table 2).

Pathway Enrichment and Protein-Protein Interactions
We performed pathway enrichment after extracting genes resulting from differentially methylated sites and regions through the WebGestalt platform (WEB-based GEne SeT AnaLysis Toolkit) with free access (30) (all pathways of this enrichment are available on Supplementary Table 3). First, we analyzed protein–protein interactions between gene products identified using the web application String (31) and plotted the interactions with Cytoscape 3.8.1 software (32). Then, a sub-enrichment analysis of the longevity regulating pathway was performed in String using the KEGG pathway database (33).

RESULTS

Study Population
In this study, eighty-seven individuals were included and classified into two groups: the CLZ-treated patients with refractory psychosis (n = 31), and the drug-naive patients with psychiatric disorders (n = 56) (Table 1). The following comorbidities were observed in CLZ-treated patients: diabetes (22.6%), epilepsy (16.1%), hyperlipidemia (12.9%), hypercholesterolemia (6.4%), hypothyroidism (6.4%), hypertension (9.7%), and obsessive-compulsive disorder (3.2%). Details about the comorbidities found in the naive patients have been previously reported (34).

Epigenetic Age in Clozapine-Treated Patients vs. Drug-Naive Patients
The variable sex did not show a significant correlation with epigenetic age; however, it was considered in the model as previous reports have demonstrated differences in the epigenetic age between men and women (23). The years of CLZ treatment correlated with epigenetic age in the PhenoAge clock (t = 2.6041, r² = 0.4415, p = 0.01458); thus, these two variables were included in the stratification of the patients. The chronological age, subtracting the chronological age from the estimated epigenetic age in all samples and by each clock.

Differentially Methylation Sites Analysis
We removed the batch effect and adjusted blood cell proportion on the normalized beta values matrix with a single-value deconvolution (champ.SVD and champ.runCombat) and a reference base analysis (champ.refbase), respectively (24, 27). Once adjusted, we analyzed differentially methylated sites analysis by linear models implemented in champ.DMP function of the ChAMP package (28). First, we analyzed differentially methylated sites considering significance at a p lower than 1e-08 (a summary of statistics is available in Supplementary Table 1). Then, after identifying differentially methylated sites, a differentially methylated region analysis was carried out with the ProbeLasso algorithm (29) (a summary of statistics is available in Supplementary Table 2).

| Characteristic               | CLZ-treated patients (n = 31) | Drug naive patients (n = 56) |
|-----------------------------|------------------------------|------------------------------|
| Age in years (mean ± DE)    | 37.74 ± 12.18                | 17.12 ± 7.84                 |
| Sex (%)                     |                              |                              |
| Male                        | 18 (58.1)                    | 13 (23.2)                    |
| Female                      | 13 (41.9)                    | 43 (76.8)                    |
| Diagnosis (%)               |                              |                              |
| Major depressive disorder   | 0                            | 19 (33.9)                    |
| Attention-deficit hyperactivity disorder | 0 | 32 (57.1) |
| Schizophrenia/early onset psychosis | 19 (61.3) | 5 (9.0) |
| Bipolar Disorder            | 3 (9.6)                      | 0                            |
| Schizoaffective Spectrum Disorder | 8 (25.8) | 0 |
| Psychotic Depressive Episode | 1 (3.2)                      | 0                            |
| Comorbidities (see text)    |                              |                              |
| Yes                         | 19 (61.3)                    | 50                           |
| No                          | 12 (38.7)                    | 6                            |
| CLZ Treatment years (mean ± DE) | 9.22 ± 7.54 | 0 (0.0) |
| Concomitant treatment (%)   |                              |                              |
| Alcohol consumption (%)     |                              |                              |
| Yes                         | 29 (93.6)                    | 0 (0.0)                      |
| No                          | 21 (67.7)                    | 56 (100)                     |
| Drugs consumption (%)       |                              |                              |
| Yes                         | 8 (25.8)                     | 0 (0.0)                      |
| No                          | 23 (74.2)                    | 56 (100)                     |
| Tobacco use (%)             |                              |                              |
| Yes                         | 14 (45.2)                    | 0 (0.0)                      |
| No                          | 17 (54.8)                    | 56 (100)                     |
| CLZ dosage (mg/day)         | 207.76 ± 128.71              | 0 (0.0)                      |

*These patients were former consumers of marijuana. + Including 1/18 patients receiving carbamazepine/phenytoin/valproate. SD, standard deviation.

### Table 1 | Clinical and demographic characteristics of all patients.
age positively correlated with the epigenetic age in all clocks, Hannum ($r^2 = 0.679, p = 4.96e-13$), Horvath ($r^2 = 0.662, p = 2.85e-12$), and PhenoAge ($r^2 = 0.664, p$-value $= 2.26e-12$) (Figure 1). After obtaining the Δage for all samples, we found that the CLZ-treated patients’ group had a smaller Δage compared with drug-naive patients (Figure 2). This difference was significant for the three analyzed clocks: Horvath ($t = -3.23, p = 0.0018$), Hannum ($t = -4.83, p = 6.0740e-06$), and PhenoAge ($t = -2.72, p = 0.0079$). Hannum’s clock showed the most significant value. The mean Δage in the CLZ-treated patients was 13.64, 9.65, and 1.54 years for Horvath, Hannum, and PhenoAge clocks, respectively. In drug-naive patients, the mean Δage was 20.77, 18.84, and 8.15 years in the same mentioned order for the three clocks.

The stratified analysis by sex and age, after comparing CLZ-treated patients vs. drug-naive patients, showed significant differences in the three clocks only for CLZ-treated male patients with mean Δage values of 13.15, 10.07, and 1.60 years for the Horvath, Hannum, and PhenoAge clocks, respectively, showing corresponding values of $p$ of 0.0376, 0.0073, and 0.0370 (Supplementary Figure 1A). The mean Δage in CLZ-treated female patients was 14.30, 9.06, and 1.47 years for the Horvath, Hannum, and PhenoAge clocks, respectively. However, significant differences were only found in Hannum’s clock ($t = -3.2253, p = 0.0035$). Thus, we did not identify differences between age subgroups (Supplementary Figure 1B).

### Comparison of Δage in Older and Younger Patients Treated With Clozapine

We explored Δage differences in CLZ-treated patients, subdivided according to the mean value of chronological age (37.74 years) and the mean treatment time with CLZ (9.22 years). Significant differences of Δage for the Horvath and Hannum clocks were observed between patients by years of CLZ treatment and chronological age (younger vs. older patients, and few years of treatment vs. many years of treatment, respectively). In addition, other significant differences were found for the Hannum clock in the following comparisons: older patients with more years of treatment (>9.22 years) vs. younger patients with

---

**FIGURE 1** | Correlation between chronological age and epigenetic age. (A) Correlation with Horvath's clock. (B) Correlation with Hannum's clock. (C) Correlation with PhenoAge’s clock.

**FIGURE 2** | Violin plots showing the comparison of Δage between clozapine (CLZ)-treated patients and drug-naive patients estimated by using epigenetic clocks of (A) Horvath, (B) Hannum, and (C) PhenoAge.
more years of treatment ($p = 0.0021$); older patients with many years of treatment vs. young patients with few years of treatment ($p = 0.0263$); and older patients with few years of treatment vs. young patients with many years of treatment ($p = 0.0236$) (Figure 3A). Regarding Horvath's clock, we only observed differences between the group of older patients with many years of treatment and younger patients with many years of treatment ($p = 0.019$) (Figure 3B).

**Differentially Methylated Sites**

We identified 44,716 differentially methylated sites between CLZ-treated patients and drug-naive patients. Of note, 39,204 CpG sites (87.70%) were hypomethylated in the CLZ-treated patients, and the remaining (5,512 CpG sites, 12.30%) were hypermethylated.

According to the position of the differentially methylated sites in relation to the gene structure, the following distribution was observed: 9,573 (24.42%) hypomethylated sites were located at 200 nucleotides of the transcriptional start site (TSS200), 7,247 (18.49%) sites on TSS1500, 7,126 (18.18%) on gene body, 5,332 (13.6%) on 5'UTR, 4,626 (11.8%) on first exon, 306 (0.78%) on 3'UTR, and 22 (0.06%) on exon binding sites. The distribution of the hypermethylated sites was as follows: 3,111 (56.44%) sites were annotated to gene body, 266 (4.83%) on 5'UTR, 265 (4.81%) on TSS1500, 262 (4.75%) on 3'UTR, 138 (2.5%) were located on the TSS200, 75 (1.36%) on first exon, and 55 (0.1%) on exon binding sites.

The location of differentially methylated sites concerning CpG islands was as follows: 29,895 (66.86%) sites on CpG islands, 7,860 sites (17.56%) on shores, 5,808 sites (12.99%) on the open sea, and 1,153 sites (2.58%) on shelves. Regarding hypomethylated sites, 29,020 of them (74%) were found on CpG islands, 6,822 (17.4%) on shores, 2,892 sites (7.38%) on the open sea, and 470 (1.2%) sites on shelves. The distribution of the hypermethylated sites was: 2,916 (52.9%) sites located on the open sea, 1,038 (18.83%) sites on shores, 875 (15.87%) sites on CpG islands, and 683 (12.39%) sites on shelves.

**Enrichment of the Genes Located Within the Differentially Methylated Sites**

In total, sixty-five pathways enriched at the hypomethylated sites were identified, and the main ones were involved in the biosynthesis of glycosaminoglycan, glioma, longevity regulatory pathway, VEGF signaling pathway, and circadian rhythm. Additionally, the hypermethylated sites are enriched on ABC transporters and endocytosis pathways (Table 2). Supplementary Table 2 contains the enrichment of all the observed pathways. Among the enriched pathways at the hypomethylated sites, the longevity pathway was identified, which, in turn, interacts with others, such as the AMPK and the insulin signaling pathways. The longevity regulating pathway occupied the 21st place of the ranked list generated by the pathway enrichment; it showed an overlap of 74 genes out of an expected 89 [$p = 1.25e-7$, false discovery rate (FDR) = 1.14e-6, and enrichment ratio = 1.4578]. We sub-analyzed the longevity regulating pathway because CLZ has been associated with a reduced mortality risk compared with other antipsychotics. For this purpose, a sub-enrichment analysis using protein–protein interaction on this pathway (Figure 4) was performed.

**Differentially Methylated Regions**

A total of 286 differentially methylated regions were identified, of which 247 regions were hypomethylated and 39 hypermethylated. Then, the FUMA platform [Functional...
Mapping and Annotation of Genome-Wide Association Studies (GWAS) (35) was used to prioritize and interpret GWAS results of the 307 annotated genes in this region. This analysis revealed top genes, such as NOTCH4, MICA, TRIM27, PBX2, and FKBPL, as enriched in GWAS of schizophrenia, CLZ-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia, and bipolar disorder among other psychiatric and non-psychiatric conditions (Supplementary Figure 2). In this enrichment analysis of the differentially methylated regions, we did not find any pathway with a statistically significant association; nevertheless, in the nominal association, twelve pathways were identified (Supplementary Figure 3).

DISCUSSION

Various analyses of DNA methylome in CLZ-treated patients have been documented in European (36, 37) and Asiatic populations (38, 39). Herein, we report the first differential methylation analysis in a Latin American population between CLZ-treated patients with refractory psychosis and drug-naive patients with psychiatric disorders. Our results showed that the proportion of hypomethylated CpG sites (87.7%) was much higher than hypermethylated ones (12.3%) in the CLZ-treated group. This finding agrees with previous studies that found a higher proportion of hypomethylated sites in patients with refractory schizophrenia treated with CLZ (40), and an increase in the global DNA hypomethylation in leukocytes obtained from patients with schizophrenia who received CLZ (41). Additional studies have reported that CLZ induces DNA demethylation at the level of specific genes; for instance, evidence suggests that CLZ may attenuate the dysregulation of GABAergic and glutamatergic transmission by reducing gene promoter hypermethylation (42, 43). These findings raise CLZ as a potential drug that deserves further investigation and, based on the screening of new potential targets in CLZ, appears to be a promising strategy for drug repurposing.

On the other hand, our results showed that patients with psychosis treated with CLZ had a lower ΔAge than those without psychopharmacological treatment. In addition, we found a significant reduction in the epigenetic age for the three studied clocks in the group of male patients; in this regard, a previous study observed the same effect of CLZ in reducing epigenetic age in male patients (23). Although the authors studied a larger sample of patients with schizophrenia in that study, they included very few CLZ users and did not perform differential methylation analysis. In this sense, the previous findings are consistent with ours. They suggested that treatment with CLZ could reduce epigenetic aging and directly impact the mortality of individuals treated with this antipsychotic.

Collectively, one of the pathways found to be hypomethylated was the estrogen signaling pathway, including the gene encoding for the estrogen receptor 1 (ESR1) (Figure 3). ESR1 is highly involved in estrogen metabolism, and differences in the frequency

### Table 2: Summary of the pathway enrichment for hypomethylated and hypermethylated sites.

| Gene set     | Pathway                        | Genes*          | FDR      | Enrichment ratio | No of genes found/expected |
|--------------|--------------------------------|-----------------|----------|------------------|----------------------------|
| Hypomethylated | Endometrial cancer            | AKT1, AKT2, APC, APC2, AXIN1, AXIN2, BAD, BAK1, BAX, BRAF | 2.4e-06  | 1.542            | 51/58                      |
|              | Mismatch repair               | EXO1, MLH1, MLH3, MSH2, MSH3, MSH6, PCNA, PMS2, POLD2, POLD3 | 6.4e-03  | 1.525            | 20/23                      |
|              | Gastric cancer                | ABCB1, AKT1, AKT2, APC, APC2, AXIN1, AXIN2, BAK1, BAX, BCL2 | 3.8e-12  | 1.494            | 127/149                    |
|              | Glycosaminoglycan biosynthesis | B3GALT6, B3GAT3, B4GALT7, CHFPE, CHFPE2, CHST11, CHST12, CHST13, CHST14, CHST3 | 1.9e-02  | 1.490            | 17/20                      |
|              | Glioma                        | AKT1, AKT2, BAK1, BAX, BRAF, CALM1, CALM2, CALM3, CALML4, CALMK2B | 4.4e-06  | 1.482            | 60/71                      |
|              | Amino sugar and nucleotide sugar metabolism | AMDH2D2, CMAS, CYB5R1, CYB5R2, CYB5R3, CYB5R4, CYB5R5, FUK, GALE, GALK1 | 3.9e-04  | 1.461            | 40/48                      |
|              | Longevity regulating pathway   | ADCY1- ADCY9, ADIPOR1, ADIPOR2, AKT1, AKT1S1, AKT2, APPL1, ATF2, ATF4, ATF6B | 1.1e-06  | 1.458            | 74/89                      |
|              | Hippo signaling pathway        | ACTB1, ACTG1, AJUBA, APC, APC2, AXIN1, AXIN2, BBC3, BIRC2, BIRC5 | 3.2e-10  | 1.446            | 127/154                    |
|              | Proteasome                     | ADRM1, POMP, PSMA1, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB10 | 1.1e-03  | 1.442            | 37/45                      |
|              | VEGF signaling pathway         | AKT1, AKT2, BAD, CASP9, CDC42, HRAS, HSPB1, JMDJ7-PLA2G4B, KDR, KRAS. | 2.8e-04  | 1.426            | 48/59                      |
| Hypermethylated | ABC transporters              | ABCA1, ABCA12, ABCA2, ABCA3, ABCA7, ABCB8, ABCB9, ABCC1, ABCC12, ABCC2 | 1.6e-04  | 3.402            | 19/44                      |
|              | Endocytosis                    | AGAP1, AP2A1, AP2A2, AP2B1, AP2M1, ARAP1, ARAP3, ARPC1B, ASAP1, ASAP2 | 1.6e-04  | 1.873            | 244/58                     |

*Only the top 10 genes of the top enriched pathways for differentially methylated sites between CLZ-treated patients and drug-naive patients are shown.
FDR, False discovery rate; No, number.
of some of its genetic variants have been associated with longevity in humans (44, 45). The DNA methylation levels in this gene may explain the difference in epigenetic age reduction only in men. Estrogen levels in a mouse model treated with 17-alpha estradiol affected metabolic parameters and delayed aging in male mice (46, 47). If CLZ induces DNA hypomethylation, it will increase ESR1 gene expression and estrogen sensitivity, which could fit in a hypothesis behind the significant epigenetic age reduction observed in our study. The longevity regulating pathway also appeared to be potentially involved in CLZ-induced epigenetic age changes. This is in line with epidemiological studies and a meta-analysis by Vermeulen et al. (48), which have reported that the long-term CLZ treatment is associated with an about 40% lower all-cause mortality compared with other antipsychotics (12, 15, 16, 49). In addition, we were able to identify enrichment of the membrane-bound adenyl cyclase enzymes (also known as adenylate cyclases) in this pathway. Contradictorily, the hypomethylation of ADCYs genes would have a similar action to that reported when these genes are inhibited. For instance, the Adcy5 knockout mouse lives longer and is used as a model of longevity (50–54). Taken together, our findings suggest that the regulation of the longevity pathway by CLZ action may promote epigenetic changes that need to be further explored. Interestingly, another group of genes found in the protein–protein interaction network analysis was related to AMP-activated protein kinases. The activation of this pathway has also been associated with longevity and aging delay (55–59).

Clozapine exhibits unique benefits for ameliorating symptoms in patients with treatment-resistant psychosis, for reducing suicide, and for improving longevity (18). This last characteristic has been observed in some epidemiological studies (14, 19, 20, 49), and in a recent study using age classifiers to drug-
induced transcriptomes that identified several geroprotectors, such as CLZ (60). Thus, despite lethal adverse reactions of CLZ, this molecule may have pro-longevity effects that should be further investigated.

Some limitations of this study should be considered. First, our sample size is small, however, this is the first study of CLZ effect on DNA methylome in Latin American patients with psychosis, and the number of CLZ-users included in other reports is still restricted and similar in numbers to ours (which is partly due to the misperception that CLZ is a dangerous therapeutic agent). Despite this, some of our results confirm previous findings from other recent studies. Second, our drug-naive patients had different psychiatric disorders and were younger than CLZ-treated patients’ group, which might influence the observed findings. Third, this is a cross-sectional study performed in a peripheral tissue, in which we did not evaluate other variables that may modulate epigenetic aging, such as prior pharmacological interventions or concomitant to CLZ that might impact DNA methylation. For instance, eight CLZ-treated patients were also receiving valproate, a drug that has been reported to be a potent epigenetic agent, affecting the DNA and histone methylation status (61). Nevertheless, due to a paucity of longitudinal epigenetic data of CLZ-treated patients, we believe that this is a good approach to evaluate the potential CLZ effects on the epigenome. In this study, we only evaluated DNA methylome, future longitudinal studies should confirm our findings and explore whether CLZ may be considered as an epigenetic drug. We could conclude that the long-term CLZ treatment might reduce epigenetic aging in male patients with psychotic disorders. In addition, our findings suggest a hypomethylation of genes of the longevity regulatory pathway as a potential action of CLZ. Thus, CLZ poses an exciting mechanism to be further explored to improve life expectancy and ameliorate the aging effects of patients treated with this antipsychotic.

DATA AVAILABILITY STATEMENT

The data presented in the study are deposited in the GEO online repository, accession numbers GSE197136 and GSE201638.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Research and Bioethics Committees of Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, the Ethics Committee of the Children’s Psychiatric Hospital Dr. Juan N. Navarro with approval No. I13/01/0913, and the Ethics Committee of the National Institute of Genomic Medicine with approval No. 06/2018/I. Furthermore, all adult participants signed informed consent. For those patients under the age of 18 years, an informed assent letter was signed by both parents/guardians and the minor.

AUTHOR CONTRIBUTIONS

NM-J, ML-L, and HN: conceptualization, resources, and project administration. BP-A, DD-O, AO-V, CA-C, YM-L, ES, IJ-R, CT-Z, and TG-C: methodology. BP-A, JM-M, and AG-M: software. BP-A and JM-M: formal analysis and data curation. BP-A, YM-L, AO-V, DD-O, JM-M, AG-M, and ES-R: investigation. BP-A, JM-M, and NM-J: writing—original draft preparation. ES-R, YM-L, and NM-J: writing—review and editing. ES-R, YM-L, AO-V, DD-O, JM-M, AG-M, BP-A, ES, IJ-R, CT-Z, TG-C, NM-J, ML-L, and HN: visualization. NM-J, ML-L, AG-M, and HN: supervision. NM-J, AG-M, ML-L, and HN: funding acquisition. All authors have read and agreed to the published version of the manuscript.

FUNDING

This work was supported by the Consejo Nacional de Ciencia y Tecnología (CONACyT) (grant no. 233695 to NM-J), the Fundación Gonzalo Rio Arronte (grant no. S591 to AG-M), the Instituto Nacional de Medicina Genómica (INMEGEN) (grant no. 06/2018/I to HN), and Universidad Autónoma Metropolitana, Xochimilco (grant no. 34605034 to ML-L). BP-A was a doctoral student from the Doctorado en Ciencias Biológicas y de la Salud at Universidad Autónoma Metropolitana, Mexico City, Mexico and was supported by CONACyT (grant No. 766012).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2022.870656/full#supplementary-material
6. Wolkowitz OM. Accelerated biological aging in serious mental disorders. *World Psychiatry* Off. (2018) 17:144–5. doi: 10.1002/wps.20546
7. Hannum G, Guinney J, Zhao L, Zhang L, Hughes G, Sadda S, et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. *Mol. Cell.* (2013) 49:559–67. doi: 10.1016/j.molcel.2012.10.016
8. Horvath S. DNA methylation age of human tissues and cell types. *Genome Biol.* (2013) 14:R115. doi: 10.1186/gb-2013-14-10-r115
9. Levine ME, Lu AT, Quach A, Chen BH, Assimes TL, Bandinelli S, et al. An epigenetic biomarker of aging for lifespan and healthspan. *Aging.* (2018) 10:573–91. doi: 10.18632/aging.101414
10. Dada O, Adanty C, Dai N, Jeremian R, Alli S, Gerretsen P, et al. Biological aging in schizophrenia and psychosis severity: DNA methylation analysis. *Psychiatry Res.* (2021) 296:113646. doi: 10.1016/j.psychres.2020.113646
11. Tandon R, Nassrallah HA, Keshavan MS. Schizophrenia, “just the facts”. 5. Treatment and prevention. Past, present, and future. *Schizophr. Res.* (2010) 122:1–23. doi: 10.1016/j.schres.2010.05.025
12. Soontornpiromjikij V, Lee EE, Jin H, Martin AS, Daly RE, Liu J, et al. Clinical correlates of insulin resistance in chronic schizophrenia: relationship to negative symptoms. *Front. Psychiatry.* (2019) 10.251. doi: 10.3389/fspyt.2019.00251
13. Khan SS, Singer BD, Vaughan DE. Molecular and physiological manifestations and measurement of aging in humans. *Aging Cell.* (2017) 16:624–33. doi: 10.1111/ace.12601
14. Schneider-Thoma J, Ettihimiou O, Huhn M, Krause M, Reichelt I, Röder M, et al. Second-generation antipsychotics and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials. *Lancet Psychiatry.* (2018) 5:653–63. doi: 10.1016/S2215-3344(18)30177-9
15. Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, et al. The clinical antipsychotic trials of intervention effectiveness (CATIE) Schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. *Schizophr. Res.* (2005) 80:9–18. doi: 10.1016/j.schres.2005.07.015
16. Torniainen M, Mittendorfer-Rutz E, Tanskanen A, Björkenstam C, Suvisaari J, Alexanderson K, et al. Antipsychotic treatment and mortality in schizophrenia. *Schizophr. Bull.* (2015) 41:656–63. doi: 10.1093/schbul/bsu164
17. Nucifora FC, Mihaljevic M, Lee BJ, Sawa A. Clozapine as a model for comethylation modules, genetic polymorphisms and clinical features in Mexican teenagers with eating disorders: preliminary results. *Nutrients.* (2021) 13:3210. doi: 10.3390/nu13093210
18. Tandon R, Nassrallah HA, Keshavan MS. Schizophrenia, “just the facts”. 5. Treatment and prevention. Past, present, and future. *Schizophr. Res.* (2010) 122:1–23. doi: 10.1016/j.schres.2010.05.025
19. Soontornpiromjikij V, Lee EE, Jin H, Martin AS, Daly RE, Liu J, et al. Clinical correlates of insulin resistance in chronic schizophrenia: relationship to negative symptoms. *Front. Psychiatry.* (2019) 10.251. doi: 10.3389/fspyt.2019.00251
20. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. *Nat. Commun.* (2017) 8:1826. doi: 10.1038/ncomms15076
21. Okazaki S, Otsuka I, Numata S, Horai T, Mouri K, Boku S, et al. Epigenetic and molecular neuroepigenetic alterations in prenatally stressed mice: relevance to molecular neuroepigenetic alterations in prenatally stressed mice. *Neural Plast.* (2019) 2019:826941. doi: 10.1155/2019/826941
22. Dong E, Matrisciano F, Grayson DR, Guidotti A. Behavioral and neurotrophic factor gene expression in the hippocampi of chronic restraint stress rats. *Neural Plast.* (2018) 2018:2682037. doi: 10.1155/2018/2682037
23. Corbo RM, Ulizzi L, Poquiziana T, Scatch AR, Association of CYP19 and ESRI pleiotropic genes with human longevity. *J. Gerontology A Biol Sci Med Sci.* (2011) 66:51–5. doi: 10.1093/gerona/glq460
24. Xu Z, Niu L, Li L, Taylor JA. ENmic: a novel background correction method for illumina humanmethylation450 beadchip. *Nucleic Acids Res.* (2016) 44:e20. doi: 10.1093/nar/gkv097
25. Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, et al. DNA methylation arrays as surrogate measures of cell mixture distribution. *BMC Bioinformatics.* (2012) 13:86. doi: 10.1186/1471-2105-13-86
26. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.* (2015) 43:e74. doi: 10.1093/nar/gkv007
27. Butcher LM, Beck S. Probe lasso: a novel method to rope in differentially methylated regions with 450K DNA methylation data. *Methods.* (2015) 72:21–8. doi: 10.1016/j.ymeth.2014.10.036
28. Liao Y, Wang J, Jashin EI, Shi Z, Zhang B. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. *Nucleic Acids Res.* (2019) 47:W199–205. doi: 10.1093/nkx401
29. Szklarczyk D, Gable AL, Lyon DJ, Jung A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res.* (2014) 42:D607–13. doi: 10.1093/gdb/jyt131
30. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res.* (2003) 13:2498–504. doi: 10.1101/gr.1239303
31. Nolasco-Rosas GA, Martínez-Magaña JJ, Juárez-Rojop IE, González-Castro TB, Tovilla-Zarate CA, García AR, et al. Association study among DNA methylation meta-analysis reveals cellular alterations in psychosis and markers of treatment-resistant schizophrenia. *Elife.* (2021) 10:e58430. doi: 10.7554/eLife.58430
32. Lee MK, Hong Y, Kim SY, London SJ, Kim WJ. DNA methylation and smoking in Korean adults: epigenome-wide association study. *Clin Epigenetics.* (2016) 8:103. doi: 10.1007/s13148-016-0266-6
33. Okazaki S, Otsuka I, Numata S, Horai T, Mouri K, Boku S, et al. Epigenetic clock analysis of blood samples from Japanese schizophrenia patients. *NPJ Schizophr.* (2019) 5:4. doi: 10.1038/s41537-019-0072-1
34. Kimshita M, Numata S, Tajima A, Yamamori H, Yasuda Y, et al. Effect of clozapine on DNA methylation in peripheral leukocytes from patients with treatment-resistant schizophrenia. *Int J Mol Sci.* (2017) 18:632. doi: 10.3390/ijms18030632
35. Melas PA, Rogdaki M, Ōsby U, Schalling M, Lavebratt C, Ekström LJ. Epigenetic aberrations in leukocytes of patients with schizophrenia: association of global DNA methylation with antipsychotic drug treatment and disease onset. *FASEB J.* (2012) 26:2712–8. doi: 10.1096/fj.11-202069
36. Dong E, Tueting P, Matrisiciano F, Grayson DR, Guidotti A. Behavioral and molecular neuroepigenetic alterations in prenatally stressed mice: relevance for the study of chromatin remodeling properties of antipsychotic drugs. *Transl Psychiatry.* (2016) 6:e711. doi: 10.1038/tip.2015.191
37. Seo MK, Kim YH, McIntyre RS, Mansur RB, Lee Y, Carmona NE, et al. Effects of antipsychotic drugs on the epigenetic modification of brain-derived neurotrophic factor gene expression in the hippocampi of chronic restraint stress rats. *Neural Plast.* (2018) 2018:2682037. doi: 10.1155/2018/2682037
38. Corbo RM, Ulizzi L, Positano L, Scarchilli R. Association of CYP19 and ESRI pleiotropic genes with human longevity. *J. Gerontology A Biol Sci Med Sci.* (2011) 66:51–5. doi: 10.1093/gerona/glq160
45. Han B, Chen H, Yao Y, Liu X, Nie C, Min J, et al. Genetic and non-genetic factors associated with the phenotype of exceptional longevity & normal cognition. Sci Rep. (2020) 10:19140. doi: 10.1038/s41598-020-75446-2

46. Garrett M, Lagerborg KA, Tsai YM, Galecki A, Jain M, Miller RA. Male lifespan extension with 17-a estradiol is linked to a sex-specific metabolomic response modulated by gonadal hormones in mice. Aging Cell. (2018) 17:e12786. doi: 10.1111/acel.12786

47. Mann SN, Hadad N, Nelson Holte M, Rothman AR, Sathiaseelan R, Ali Garratt M, Lagerborg KA, Tsai YM, Galecki A, Jain M, Miller RA. Male lifespan extension with 17-a estradiol is linked to a sex-specific metabolomic response modulated by gonadal hormones in mice. Aging Cell. (2018) 17:e12786. doi: 10.1111/acel.12786

48. Vermeulen JM, van Rooijen G, van de Kerkhof MPJ, Sutterland AL, Correll CU, Tiihonen J. Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 years. Schizophr Bull. (2019) 45:315–29. doi: 10.1093/schbul/sby052

49. Taipale H, Tanskanen A, Mehtälä J, Vattulainen P, Correll CU, Tiihonen J. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry. (2020) 19:61–8. doi: 10.1002/wps.20699

50. De Lorenzo MS, Chen W, Baljinnyam E, Carlini MJ, La Perle K, Bishop SP, et al. Reduced malignancy as a mechanism for longevity in mice with adenylyl cyclase type 5 disruption. Aging Cell. (2014) 13:102–10. doi: 10.1111/acel.12152

51. Vaupel JS, Pachon RE, Vaupel J. Inhibition of adenylyl cyclase type 5 increases longevity and healthful aging through oxidative stress protection. Oxid Med Cell Longev. (2015) 2015:250310. doi: 10.1155/2015/250310

52. Vaupel JS, Yan L, Ishikawa Y, Vaupel J, Sadoshima J. Adenylyl cyclase type 5 disruption prolongs longevity and protects the heart against stress. Circ J. (2009) 73:195–200. doi: 10.1253/circj.cj-08-0957

53. Yan L, Park JY, Dillingger JG, De Lorenzo MS, Yuan C, Bai L, et al. Common mechanisms for calorie restriction and adenylyl cyclase type 5 knockout models of longevity. Aging Cell. (2012) 11:1110–20. doi: 10.1111/acel.12013

54. Yan L, Vaupel J, O’Connor JP, Ivesa A, Ge H, Chen W, et al. Type 5 adenylyl cyclase disruption increases longevity and protects against stress. Cell. (2007) 130:247–58. doi: 10.1016/j.cell.2007.05.038

55. Apfeld J, O’Connor G, McDonagh T, D’s Stefano PS, Curtis R. The AMP-activated protein kinase AAK-2 links energy levels and insulin-like signals to lifespan in C. elegans. Genes Dev. (2004) 18:3004–9. doi: 10.1101/gad.1255404

56. Burkewitz K, Weir HM, Mair WB. AMPK as a pro-longevity target. Exp Suppl. (2016) 107:227–56. doi: 10.1007/978-3-319-43589-3_10

57. Greer EL, Banko MR, Brunet A. AMP-activated protein kinase and FoxO transcription factors in dietary restriction-induced longevity. Ann N Y Acad Sci. (2009) 1170:688–92. doi: 10.1111/j.1749-6632.2009.04019.x

58. Morganova GV, Klebanov AA. Age-related AMP-activated protein kinase alterations: from cellular energetics to longevity. Cell Biochem Funct. (2019) 37:169–76. doi: 10.1002/cbf.3384

59. Stancu AL. AMPK activation can delay aging. Discov Med. (2015) 3:e53. doi: 10.15190/dm.2015.45

60. Janssens GE, Lin X, Millan-Ariño L, Kavlek A, Sen I, Seinstra RJ, et al. Transcription-based screening identifies pharmacological inhibition of Hsp90 as a means to defer aging. Cell Rep. (2019) 27:467–80.e. doi: 10.1016/j.celrep.2019.03.044

61. Mello MLS. Sodium valproate-induced chromatin remodeling. Front Cell Dev Biol. (2021) 9:e45518. doi: 10.3389/fcell.2021.645

Conflicts of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Pérez-Aldana, Martínez-Magaña, Mayén-Lobo, Dávila-Ortíz de Montellano, Aviña-Cervantes, Ortega-Vázquez, Genis-Mendoza, Sarmiento, Soto-Reyes, Juárez-Rojop, Tovilla-Zarate, González-Castro, Nicole, López-López and Monroy-Jaramillo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.